Disclosure of Alzheimer's disease (AD) biomarkers to cognitively unimpaired adults are
currently conducted only in research settings. Yet, US Food and Drug Administration approval of …

Disclosure of personal disease‐related information to asymptomatic adults has been debated
over the last century in medicine and research. Recently, Alzheimer's disease (AD) has …

Alzheimer's disease (AD) begins with an asymptomatic “preclinical” phase, in which abnormal
biomarkers indicate risk for developing cognitive impairment. Biomarker information is …

An accurate blood test for Alzheimer’s disease that is sensitive to preclinical proteinopathy
and cognitive decline has clear implications for early detection and secondary prevention. We …

This study investigated differences in retrospective cognitive trajectories between amyloid
and tau PET biomarker stratified groups in initially cognitively unimpaired participants …

Introduction This study applies a novel algorithm to longitudinal amyloid positron emission
tomography (PET) imaging to identify age‐heterogeneous amyloid trajectory groups, estimate …

Introduction Increased availability of Alzheimer's disease (AD) biomarker tests provides
older adults with opportunities to seek out and learn results. We evaluated the feasibility of …

Background This study tested if central obesity, hypertension, or depressive symptoms
moderated the relationship between β-amyloid (Aβ) and longitudinal cognitive performance in …

Hydroxylamine metabolites, implicated in dose-dependent and idiosyncratic toxicity from
arylamine drugs, and amidoximes, used as pro-drugs, are metabolized by an as yet …

Background Insulin resistance (IR) and type 2 diabetes have been found to increase the risk
for Alzheimer’s clinical syndrome in epidemiologic studies but have not been associated …